About 6 results found for searched term "LK-44" (0.127 seconds)
Cat.No. | Name | Target |
---|---|---|
M24696 | Ascrinvacumab | ALK |
Anti-ACVRL1/ALK-1 Reference Antibody; PF-03446962 | ||
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC). | ||
M42988 | LK-44 | Others |
hCES2A-IN-2 is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). | ||
M55680 | Recombinant Human PSA/KLK3 Protein (HEK293, 244AA, C-6His) | Cytokines and Growth Factors |
Prostate-Specific Antigen; Seminin; Kallikrein-3; P-30 Antigen | ||
Recombinant Human PSA/KLK3 is a member of serine proteases having diverse physiological functions. Kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. Its encoded protein is secreted and may play a role in suppression of tumorigenesis in breast and prostate cancers. | ||
M4240 | Shikonin | TNF Receptor |
C.I. 75535; Isoarnebin 4; CAS# 54952-43-1 | ||
Shikonin (C.I. 75535, Anchusin, Anchusa acid, Alkanna Red, Isoarnebin 4, NSC 252844) is an effective and specific inhibitor of Pyruvate kinase M2 (PKM2). Shikonin is the main ingredient of Lithosia, a Chinese herb with a variety of biological activities. Shikonin acts as an anti-inflammatory by inhibiting tumor necrosis factor-α (TNF-α), Proteasome can inhibit the activation of nuclear factor-κB (NF-κB) signaling pathway. | ||
M8071 | PF-6422899 | Others |
PF-6422899 is an alkynylated derivative of PF-6274484; irreversible inhibitor of EGFR kinase activity. | ||
M29632 | M4K2234 | ALK |
M4K2234 (compound 26b) is an ALK2 inhibitor. M4K2234 inhibits ALK2 and ALK5 with IC50s of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for ALK1 and ALK2 protein kinases. M4K2234 can be used for the research of cancer. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.